Literature DB >> 3032623

Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.

D Andreu, R B Merrifield.   

Abstract

In an effort to find analogs of glucagon that would bind to the glucagon receptor of the rat liver membrane but would not activate membrane-bound adenyl cyclase, several hybrid molecules were synthesized which contained sequences from both glucagon and secretin. [Asp3, Glu9]Glucagon and [Asp3, Glu9, Arg12]glucagon were inactive in the adenyl cyclase assay even at high concentrations but retained some binding affinity for the receptor. They were able to displace 125I-glucagon completely from its receptor and could completely inhibit the activation of adenyl cyclase by natural or synthetic glucagon. The inhibition index [I/A]50 was approximately 110 for both analogs. [Asp3]Glucagon, [Glu3]glucagon and [Asp3, Lys17, 18, Glu21]glucagon were weak partial agonists, while [Asp3, Glu21]glucagon was inactive and a poor inhibitor. The peptides were synthesized by solid-phase methods and purified to homogeneity by reverse-phase high-performance liquid chromatography on C18 silica columns. These are the first fully synthetic competitive glucagon antagonists to be reported.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032623     DOI: 10.1111/j.1432-1033.1987.tb11167.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  2 in total

1.  Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.

Authors:  Jason Perret; Mélanie Van Craenenbroeck; Ingrid Langer; Pascale Vertongen; Françoise Gregoire; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

2.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.